Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.

Abstract: A method, a system, and an article are provided for identification of security-related activities based on usage of a plurality of independent cloud-based, hosted application platforms. An example method includes: receiving, from the application platforms, activity data and state data for a plurality of users of the application platforms; generating one or more predictive models configured to detect deviations from normal user behavior across the application platforms; providing, as input to the one or more predictive models, the activity data and the state data for at least one of the users; receiving, from the one or more predictive models, an indication that an activity of the at least one of the users deviates from the normal user behavior; and facilitating a remedial action to address the indicated deviation.

Abstract: Methods are provided for reducing the frequency of migraine attacks in a subject who has frequent migraine headaches with or without aura. The methods comprise intranasally administering to the subject a pharmaceutical composition comprising dihydroergotamine (DHE) or salt thereof on a repeat dose schedule, wherein each intranasal administration is delivered by a manually actuated, propellant-driven, metered-dose administration device, and wherein the schedule is a chronic intermittent schedule in which each of the repeated administrations is performed while the subject is experiencing a migraine headache.

Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.

Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.

Abstract: A deliver device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.

Abstract: A method, a system, and an article are provided for identification of security-related activities based on usage of a plurality of independent cloud-based, hosted application platforms. An example method includes: receiving, from the application platforms, activity data and state data for a plurality of users of the application platforms; generating one or more predictive models configured to detect deviations from normal user behavior across the application platforms; providing, as input to the one or more predictive models, the activity data and the state data for at least one of the users; receiving, from the one or more predictive models, an indication that an activity of the at least one of the users deviates from the normal user behavior; and facilitating a remedial action to address the indicated deviation.

Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax(Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.

Abstract: A system comprising a payment account generated by the payor and adapted to receive the payment from the payor and transfer the payment to the payee in at least one form of payment, a funding account to provide funds to a fund holding account which is adapted to provide the payment to the payment account, a payment processor to process the payment from the payor to the payment account and process the payment from the payment account to the payee, and a payee portal to be accessed by the payee and receive the payment from the payment account. The payment account is a dedicated account for only the payee, and the payee self-directs the transfer of funds and controls the form of payment made from the payment account. A method further comprising generating a payment account, providing funds to the payment account, and self-directing funds from the payment account.

Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.

Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

Abstract: Methods are provided for reducing the frequency of migraine attacks in a subject who has frequent migraine headaches with or without aura. The methods comprise intranasally administering to the subject a pharmaceutical composition comprising dihydroergotamine (DHE) or salt thereof on a repeat dose schedule, wherein each intranasal administration is delivered by a manually actuated, propellant-driven, metered-dose administration device, and wherein the schedule is a chronic intermittent schedule in which each of the repeated administrations is performed while the subject is experiencing a migraine headache.

Abstract: A method, a system, and an article are provided for identification of security-related activities based on usage of a plurality of independent cloud-based, hosted application platforms. An example method includes: receiving, from the application platforms, activity data and state data for a plurality of users of the application platforms; generating one or more predictive models configured to detect deviations from normal user behavior across the application platforms; providing, as input to the one or more predictive models, the activity data and the state data for at least one of the users; receiving, from the one or more predictive models, an indication that an activity of the at least one of the users deviates from the normal user behavior; and facilitating a remedial action to address the indicated deviation.

Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

Abstract: A method, a system, and an article are provided for identification of security-related activities based on usage of a plurality of independent cloud-based, hosted application platforms. An example method includes: receiving, from the application platforms, activity data and state data for a plurality of users of the application platforms; generating one or more predictive models configured to detect deviations from normal user behavior across the application platforms; providing, as input to the one or more predictive models, the activity data and the state data for at least one of the users; receiving, from the one or more predictive models, an indication that an activity of the at least one of the users deviates from the normal user behavior; and facilitating a remedial action to address the indicated deviation.

Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.

Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.

Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.